PDL BIOPHARMA, INC.
Presentation Operator MessageOperator (Operator)Welcome to the PDL BioPharma Third Quarter 201...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
PDL BioPharma, Inc. has a portfolio of income generating assets based on alternative financings. These alternative financings fall into one of three categories: royalty monetization, debt structures and hybrids of the two. The Company's investments are typically in assets with strong intellectual property protection and are commercial stage or soon-to-be approved. The counterparties in these transactions can be biotechs, pharmas, medtech companies, universities and inventors.
| 1st Jan change | Capi. | |
|---|---|---|
| +34.74% | 50.85B | |
| +0.61% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +10.85% | 26.11B | |
| -21.57% | 19.13B | |
| +8.73% | 13.05B | |
| +26.98% | 12.16B | |
| +24.38% | 12.08B |
